drugset / Trial / NCT00360854

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

NCT00360854 ↗

Phase 1 Unknown 48 enrolled Children's Cancer and Leukaemia Group
Non-randomizedOpen-labelTreatment

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving erlotinib together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib when given alone or together with radiation therapy in treating young patients with refractory or relapsed malignant brain tumors or newly diagnosed brain stem glioma.

Timeline

Start
2005-05
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule — Oral